CBYL719F12201: EPIK-P2 Phase II double-blind study w/ upfront 16-week randomized placebo-controlled period to assess efficacy safety & pharmacokinetics of alpelisib (BYL719) in pediatric & adult patients w/ PIK3CA-related overgrowth spectrum (PROS)

Brief description of study

CBYL719F12201: EPIK-P2, Phase II double-blind study w/ upfront 16-week randomized, placebo-controlled period, to assess efficacy, safety & pharmacokinetics of alpelisib (BYL719) in pediatric & adult patients w/ PIK3CA-related overgrowth spectrum (PROS)


Clinical Study Identifier: s20-00302
ClinicalTrials.gov Identifier: NCT04589650
Principal Investigator: Francine Blei.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.